Eli Lilly's Centessa Purchase at Nearly $8 Billion Makes VVOS the Most Undervalued Nasdaq Company
Executive Summary On March 31, 2026, Eli Lilly announced a definitive agreement to acquire Centessa Pharmaceuticals (NASDAQ: CNTA) for up to $7.8 billion ($6.3B upfront + $1.5B in CVRs), representing a 70% premium to the prior close. The acquisition targets Centessa's orexin receptor 2 (OX2R) agonist